Compositions, methods and uses for poxvirus elements in vaccine constructs
Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
1. An immunogenic pharmaceutical composition for administration to a subject comprising:
one or more constructs, comprising:
a modified or attenuated vaccinia virus construct encoding at least one vaccinia virus secretory signal sequence associated with at least one immunogenic non-vaccinia virus peptide
wherein the at least one vaccinia virus secretory signal sequence comprises, at least one of a secretory signal sequence of C13L or B8R, and
a pharmaceutically acceptable excipient,
wherein the one or more peptides are capable of inducing an immune response in the subject.
2. The immunogenic composition of claim 1 , wherein the non-vaccinia virus peptide is derived from bacteria, virus, mammals, fungi, protozoan, non-pathogenic organisms or a combination thereof.
3. The immunogenic composition of claim 1 , wherein the non-vaccinia virus peptide comprises an influenza protein.
4. The immunogenic composition of claim 3 , wherein the influenza protein comprises hemagglutinin (HA), neuraminidase (N), nucleoprotein (NP), matrix (M) or a combination thereof.
5. The immunogenic composition of claim 1 , wherein the construct is a modified vaccinia Ankara (MVA) virus.
6. The immunogenic composition of claim 1 , further comprising one or more translational control sequences.
7. A method for inducing an immune response in a subject comprising:
administering the immunogenic composition of claim 1 to the subject in an amount sufficient to induce an immune response in the subject.
8. The method of claim 7 , wherein the modified vaccinia virus is a modified vaccinia Ankara (MVA).
9. A method for inducing an immune response in a subject comprising:
administering the immunogenic composition of claim 1 as a first composition to the subject in an amount sufficient to induce an immune response, followed by administering a second composition to the subject, the second composition comprising: a modified or attenuated vaccinia virus construct encoding one or more poxvirus constructs, comprising, at least one poxvirus secretory signal sequence and at least one non-poxvirus peptide,
wherein the composition is capable of inducing an immune response in the subject when administered in an amount sufficient to induce an immune response.
10. The method of claim 9 , wherein the vaccinia virus in the first composition is a modified vaccinia Ankara (MVA).
11. The method of claim 9 , wherein the non-poxvirus peptide is derived from bacteria, virus, mammals, fungi, protozoan, non-pathogenic organisms or a combination thereof.
12. The method of claim 9 , wherein the first composition is administered to the subject 6 months or less prior to the second composition.
13. A method for inducing an immune response in a subject previously exposed to poxvirus comprising:
administering as a pre-boost dosage, the immunogenic composition of claim 1 to the subject in an amount sufficient to induce an immune response,
wherein the vaccinia virus is a modified vaccinia Ankara (MVA).
14. The method of claim 13 , further comprising administering a booster dosage of the immunogenic composition 6 months or less after administration of the pre-boost dosage of the immunogenic composition.
15. The method of claim 13 , wherein administration of the immunogenic composition comprises intradermal administration.
16. A kit comprising;
the immunogenic composition of claim 1 ; and at least one container.
17. The kit of claim 16 , wherein at least one of the non-vaccinia virus peptides comprises one or more influenza virus protein(s).
18. A pharmaceutical composition for administration to a subject comprising:
one or more constructs, comprising: a modified or attenuated vaccinia virus construct encoding at least one vaccinia virus secretory signal sequence associated with at least one non-vaccinia virus peptide, wherein the at least one vaccinia virus secretory signal sequence is a secretory signal of C13L, and
a pharmaceutically acceptable excipient, wherein the one or more peptides are capable of inducing an immune response in the subject.
19. The pharmaceutical composition of claim 18 , wherein the secretory signal sequence from C13L is the amino acid sequence represented by SEQ ID NO:1.